We would love to hear your thoughts about our site and services, please take our survey here.
The business has never been customer facing, that's a different type of business. If you look at their hearing loss test and HCV test, they're partnering players who are already in the market and can take on that role - it takes out a whole layer out of the business and personally I think it makes sense.... time will tell. Sales will come, remember after COVID the business needs to run as it always has, so no point engaging more staff to service customer support... my view.
GDRs strategy is B2B not B2C. They want a few large contracts with a few partners rather than lots of contracts with smaller group. They ave highlighted a health ministry in the EU, a partnership with a high volume automation partner Beckman in the US, and a Gates funded provide DIVOC in India. These largely depend on approvals, once in these represent an ongoing and significant revenue stream without the need for GDR to manage customers, they are not a B2C business. Soon we shall see the merit of this approach.
GDRs strategy is B2B not B2C. They want a few large contracts with a few partners rather than lots of contracts with smaller group. They ave highlighted a health ministry in the EU, a partnership with a high volume automation partner Beckman in the US, and a Gates funded provide DIVOC in India. These largely depend on approvals, once in these represent an ongoing and significant revenue stream without the need for GDR to manage customers, they are not a B2C business. Soon we shall see the merit of this approach.
There'll be lots of businesses in the same boat since many are based on the same WHO recommended sequences. Hopefully GDR will be quick to confirm their test is immune or handles the mutations if they occur within the regions used, come on DB, please get this level of information out to provide some positive news for us GDR LTHs and play to the strengths of the GDR test!! You have a lot of support here, think creatively about putting out more news flow
I am sure GDR will make a non-RNS announcement about the new variant. If the 17 mutations do not sit within the test sites, then it will not be affected. They don't need to run samples in that instance and they can can simply state 'the mutations in the new variant identified in the UK to fall under the sequences used in the GDR test', it does not require an RNS imo
Kaeren, my feedback is some of the LFD indeed are not picking up this new variant and that this is accounting for some of the poor performance, I'm sure as more data is collected this will become more evident. With a mutating virus this is always an issue, the wide spread distribution of the virus puts us into unknown territory, if the LFDs are being thrown off then the vaccine is likely to be problematic too... PCR and sequencing is going to be the order of the day...
ThePunter, yes good news for companies with molecular tests, not so good for companies with antigen tests. I know you were trying to suggest GDR wouldn't benefit because of the time its taken, my opinion is that this will soon be different and sales will come very shortly as approvals come in and sales channels open up as a consequence. I know you don't share that opinion, that's ok. Stay safe
Hopefully people will recognise the importance of the discussions we’ve had on this board over the last few months around mutations.
I thought it would be good to put this into perspective with regard to testing.
Mutations will eventually create a variant that overcomes the vaccine. The very act of vaccination will create a positive selection pressure on variants that overcome the vaccine. It’s irresponsible not to consider this.
What does this mean with regard to testing?
Testing will not go away, we need very good granularity on how the virus is spreading.
Antigen tests use the same process as antibodies, they detect a surface feature on the outside of the virus, generally the spike protein. Mutations can invade the immune response by changing this protein structure. Same for antigen tests. What’s not widely considered is a mutation variant can also make antigen tests less sensitive.
That’s why PCR based tests and other molecular tests are so important. They are developed (should be) to regions that don’t change and therefore are less susceptible to variant changes.
Bottom line, testing is here to stay, mutations make antigen tests potentially open to failure, molecular tests like the GDR test and NCYT are the best change of surveillance and we need a lot of testing to keep the economy open.
The new variant shows it’s a matter of time before we will need a new vaccine. The virus will mutate faster than we can create new vaccine candidates. There’s a long way to go everyone, we need to be realistic about this and accept we have years of this ahead of us.
or apple and the iPod and iPhone, they we far from first to market in the music player and smart phone markets, but they produced the best.... you can find metaphors for whatever you want.
GDR will succeed, great product, great partners, now able to sell in the US.
Thanks Muck for sharing.
Allah, the betamax VHS argument is not valid in my opinion, the GDR test is a PCR based test and use the same qPCR platform. It's more akin to a film taking longer to produce. Doesn't mean there isn't an audience for it when it comes out, some people are anticipating its arrival in fact. LTHs hoping it brings in a lot of ticket sales :)